USE OF MONOCLONAL ARTICLES IN ASTHMA: A THERAPEUTIC OPTION

Authors

DOI:

https://doi.org/10.47820/recima21.v5i10.5790

Keywords:

Severe and refractory asthma. Monoclonal antibodies. Eosinophilic asthma.

Abstract

Asthma is a pathology with great prevalence in society that has a significant impact on its daily problems. It manifests itself in different degrees, and can be classified based on the treatment necessary for its control. About 5-10% of patients do not respond to therapy with inhale corticosteroids, long-acting bronchodilators and anticholinergics, making additional measures necessary. Objective: The present study aims to emphasize that patients with severe asthma or eosinophilic asthma can benefit from treatment with immunobiologicals. Method: The article was based on selected works on the PubMed, Scielo, Google academic and journal platforms, using the descriptors “asthma”, “asthma treatment” and “monoclonal antibodies in asthma”. Considering updated and practical studies.

Downloads

Download data is not yet available.

Author Biographies

Izabella de Sousa Borges

Médica pelo Centro Universitário Atenas.

Victor Rabelo Bitencourt

Médico pelo Centro Universitário Atenas.

Renata Silveira Rosa, Centro Universitário Atenas

Médica pelo Centro Universitário Atenas.

Lucas Camargos Carvalho

Médico pelo Centro Universitário Atenas.

References

COSTA, E. et al. Guideline for the management of severe asthma. Brazilian Journal of Allergy and Immunology (BJAI), v. 3, n. 5, 2015. DOI: https://doi.org/10.5935/2318-5015.20150025

FITZGERALD, J. M. et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet, v. 388, n. 10056, p. 2128–2141, out. 2016. DOI: https://doi.org/10.1016/S0140-6736(16)31322-8

HALDAR, P. et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis. Journal of Allergy and Clinical Immunology, v. 133, n. 3, p. 921-923, mar. 2014. DOI: https://doi.org/10.1016/j.jaci.2013.11.026

ORTEGA, H. G. et al. Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. New England Journal of Medicine, v. 371, n. 13, p. 1198-1207, 25 set. 2014 DOI: https://doi.org/10.1056/NEJMoa1403290

SECRETARIA DE SAÚDE DO DISTRITO FEDERAL. Asma: o mal na asma grave e de dificil controle. Brasilia: Secretária de Saúde do Distrito Federal, 2018. Disponível em: http://www.saude.df.gov.br/wp-conteudo/uploads/2018/04/ASMA-Omalizumabe-na-Asma-Grave-e-de-Dificil-Controle.pdf. Acesso em: 22 set. 2024.

SOPTERJ. Protocolo de diagnóstico e tratamento de Asma da Sociedade do Estado do Rio de Janeiro. Rio de Janeiro: SOPTERJ, 2018. Disponível em: http://www.sopterj.com.br/wpcontent/uploads/2018/04/protocolo-asma-SOPTERJ-2018-abril.pdf. Acesso em: 22 set. 2024.

Downloads

Published

10/10/2024

How to Cite

de Sousa Borges, I., Rabelo Bitencourt, V., Silveira Rosa, R., & Camargos Carvalho, L. (2024). USE OF MONOCLONAL ARTICLES IN ASTHMA: A THERAPEUTIC OPTION. RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218, 5(10), e5105790. https://doi.org/10.47820/recima21.v5i10.5790

Issue

Vol. 5 No. 10 (2024): CLICK HERE TO ACCESS THE ARTICLES

Section

REVIEWS - TRANSLATIONS - INTERVIEWS

Categories

License

Copyright (c) 2024 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores  e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.